Before anything else
The 10-K for fiscal year 2025 shows Zoetis earning its widest net margin in five years, keeping more than 28 cents of every sales dollar as profit. The stock has fallen sharply over the past several months. A business getting more efficient and a price that implies the opposite cannot both be telling the truth, and that disagreement is the story.
A company built on one idea
Zoetis was spun out of Pfizer in 2013 on a single conviction: that pet owners and livestock farmers would pay reliably for medicines, through recessions and pandemics alike, because animals get sick on no particular schedule. For most of the decade that followed, the market agreed enthusiastically, pricing the stock at a multiple, the price tag per dollar of profit, that sat well above the broader market. Then, in 2025 and into 2026, something shifted in the mood even as the math, what the filed numbers actually show, kept improving.
That gap between a strengthening business and a collapsing price is what the filings now force us to examine.
What the year’s arc shows
The fiscal 2025 annual filing recorded $9.5 billion in revenue, up modestly from the prior year. Growth slowed, but profitability did not. Net margin reached 28.2%, the best reading in the five-year run our data covers, meaning the company is squeezing more profit from each dollar of sales even as top-line momentum cools. Think of it as a restaurant that seats fewer new tables but earns more on every meal it does serve.
The Q2 2026 filing, the most recent quarter available as of today, adds texture. Revenue for the quarter came in essentially flat year-over-year. Beneath that flat headline, two forces pulled in opposite directions.
Where the cracks appeared
U.S. dermatology revenue fell sharply in Q2 2026 compared to the same quarter a year earlier, according to the Q2 earnings release. Dermatology, primarily the allergy drug Apoquel and the injectable Cytopoint, had been Zoetis’s fastest-growing franchise for years. Price sensitivity and new competition are now biting. For a company whose domestic companion-animal business carries its highest margins, a meaningful drop in its premium segment is not a footnote.
The offsetting news is real, though. Companion animal diagnostics and livestock revenue both grew at a healthy clip in the same quarter, the latter partly because poultry vaccine demand jumped during a disease outbreak. International parasiticides, including Simparica Trio, the once-monthly flea, tick, and heartworm tablet that became a household name among dog owners, continued to gain ground abroad even as U.S. sales faced pressure. The business is not shrinking uniformly; it is rotating.
The balance sheet question
A company can post improving margins while quietly borrowing its way to trouble. The filings do not show that here. The 2025 10-K shows earnings per share rising roughly ten percent year-over-year, a gain achieved even as revenue growth slowed to low single digits. That combination, faster profit growth than revenue growth, is the signature of a business with pricing power and cost discipline, not one in distress.
Our data puts the current price-to-earnings multiple at 12.4 times. A multiple is simply how many dollars the market pays for each dollar of annual profit. At its current level, the market is paying historically little for each dollar of Zoetis profit. Whether that reflects a permanent reassessment of the business or a temporary mood swing is the open question the filings alone cannot answer.
Reading the numbers
- Net margin, FY2025: 28.2%. What it is: the share of each sales dollar left after every cost, tax, and interest payment. What it means here: Zoetis kept more per dollar of sales in 2025 than in any prior year in our dataset. Everyday version: a shop that takes in $100 and keeps $28.20 after paying everyone, up from $26.90 the year before.
- U.S. dermatology revenue, Q2 2026: down 16% year-over-year. What it is: the change in sales from Zoetis’s skin and allergy drug franchise in the United States. What it means here: the company’s highest-profile growth engine is losing ground to price pressure and competition. Everyday version: a coffee shop’s signature drink, which drove most of its growth, suddenly sells 16% fewer cups because a rival opened next door at a lower price.
- P/E ratio: 12.4 times. What it is: the price-to-earnings multiple, or how many dollars the market pays for each dollar of annual profit. What it means here: the stock is priced at a historically compressed valuation even as profits per share hit a new high. Everyday version: a rental property that earns $10,000 a year is being offered at a price that implies the buyer expects little future growth.
The data cannot tell us whether dermatology recovers, whether international growth fully offsets U.S. pressure, or whether the multiple re-expands. Those are the questions the next two or three quarters will answer. If the margin holds and dermatology stabilizes, the gap between the math and the mood is wide. If dermatology keeps sliding, the math starts to look less settled than the 2025 annual filing suggests.
For the standing yardsticks on Zoetis: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Zoetis.
Sources
- Zoetis 10-Q, quarter ended June 30, 2026
- Zoetis 10-K, fiscal year ended December 31, 2025
- Zoetis 10-K, fiscal year ended December 31, 2024
- Zoetis Q2 2026 earnings release
- Zoetis SEC EDGAR filing index
